Cardinal Health (NYSE:CAH) CEO Jason Hollar Sells 80,000 Shares

Cardinal Health, Inc. (NYSE:CAH) CEO Jason Hollar sold 80,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the completion of the transaction, the chief executive officer directly owned 235,132 shares in the company, valued at $55,430,017.68. This trade represents a 25.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Cardinal Health Stock Performance

NYSE CAH opened at $228.95 on Friday. Cardinal Health, Inc. has a 52-week low of $145.87 and a 52-week high of $258.30. The company has a 50-day simple moving average of $231.91 and a 200 day simple moving average of $217.78. The company has a market capitalization of $53.25 billion, a PE ratio of 31.67, a price-to-earnings-growth ratio of 1.26 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last released its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The firm had revenue of $63.67 billion for the quarter, compared to analysts’ expectations of $65.15 billion. During the same period in the previous year, the company earned $2.08 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, analysts forecast that Cardinal Health, Inc. will post 12.54 EPS for the current fiscal year.

Cardinal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be paid a $0.5158 dividend. This represents a $2.06 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Thursday, October 1st. Cardinal Health’s payout ratio is currently 28.49%.

Institutional Investors Weigh In On Cardinal Health

Several hedge funds and other institutional investors have recently modified their holdings of the stock. LWM Advisors Inc. increased its stake in shares of Cardinal Health by 4.4% during the second quarter. LWM Advisors Inc. now owns 1,028 shares of the company’s stock valued at $244,000 after purchasing an additional 43 shares in the last quarter. Kathmere Capital Management LLC boosted its position in shares of Cardinal Health by 1.2% in the 1st quarter. Kathmere Capital Management LLC now owns 4,242 shares of the company’s stock worth $896,000 after purchasing an additional 49 shares in the last quarter. Hillsdale Investment Management Inc. boosted its position in shares of Cardinal Health by 0.9% in the 4th quarter. Hillsdale Investment Management Inc. now owns 5,760 shares of the company’s stock worth $1,184,000 after purchasing an additional 50 shares in the last quarter. V Square Quantitative Management LLC grew its stake in shares of Cardinal Health by 2.6% in the 1st quarter. V Square Quantitative Management LLC now owns 2,002 shares of the company’s stock worth $423,000 after buying an additional 50 shares during the last quarter. Finally, Generali Asset Management SPA SGR increased its position in Cardinal Health by 11.0% during the 4th quarter. Generali Asset Management SPA SGR now owns 513 shares of the company’s stock valued at $105,000 after buying an additional 51 shares in the last quarter. 87.17% of the stock is currently owned by institutional investors.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage of Cardinal Health with a “moderate buy” or outperform-equivalent rating. RBC cited the integration of higher-margin services as a potential driver of future earnings outperformance. RBC Capital Starts Cardinal Health at Outperform
• Positive Sentiment: A Zacks analysis identified CAH as a potentially attractive long-term value stock, while recent coverage has highlighted Cardinal Health’s precision-medicine operations and higher-margin services as sources of sustained growth. Why Cardinal Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: Brokerages continue to assign Cardinal Health a consensus “moderate buy” rating. The constructive view is tempered by valuation and questions about the sustainability of recent earnings gains.
• Negative Sentiment: Multiple executives and insiders sold shares around $235–$237. Chief Executive Officer Jason Hollar sold a combined 124,529 shares worth approximately $29.4 million, while CEO Deborah Weitzman sold about $1.7 million. Other insider sales included Chief Accounting Officer Mary Scherer and executives Michelle Greene, Jessica Mayer, and Stephen Mason. The transactions substantially reduced several executives’ holdings and may signal that insiders are taking profits after the stock’s strong rally. Cardinal Health Insider Sale Filing
• Negative Sentiment: Although Cardinal Health reported adjusted quarterly EPS of $2.91, well above the $2.42 consensus, an analysis noted that a significant portion of the earnings improvement came from a one-time tariff refund. That raises concerns about the durability of the earnings beat and may be contributing to the weaker stock performance. Cardinal Health Earnings Analysis

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CAH. Royal Bank Of Canada began coverage on shares of Cardinal Health in a research note on Wednesday. They issued an “outperform” rating and a $276.00 target price for the company. Leerink Partners set a $292.00 price target on shares of Cardinal Health in a research note on Tuesday, August 11th. UBS Group raised their price objective on shares of Cardinal Health from $274.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. lifted their price objective on shares of Cardinal Health from $215.00 to $260.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Finally, Robert W. Baird boosted their target price on shares of Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Cardinal Health has a consensus rating of “Moderate Buy” and a consensus target price of $266.56.

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.